Omeros Corporation News Releases https://investor.omeros.com/ Omeros Corporation News Releases en Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-ebmt-case-report-resolution -- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of Wed, 03 Apr 2019 08:30:00 -0400 Omeros Corporation News Releases 11621 Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-upcoming-educational-event-annual --Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Tue, 19 Mar 2019 08:30:00 -0400 Omeros Corporation News Releases 11616 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-reports-fourth-quarter-and-year-end-2018 – Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan Fri, 01 Mar 2019 07:30:00 -0500 Omeros Corporation News Releases 11581 Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019 https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announce-fourth-quarter-and-year-end-2018 SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens. Tue, 26 Feb 2019 07:00:00 -0500 Omeros Corporation News Releases 11571 Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721 https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-usan-and-inn-selection SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary Wed, 20 Feb 2019 08:30:00 -0500 Omeros Corporation News Releases 11566 Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-streamlines-path-biologics-license Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has Thu, 14 Feb 2019 08:30:00 -0500 Omeros Corporation News Releases 11561 Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-appoints-thomas-f-bumol-phd-board-directors -- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors. Tue, 12 Feb 2019 08:30:00 -0500 Omeros Corporation News Releases 11521 Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy https://investor.omeros.com/news-releases/news-release-details/omeros-finalizes-fda-clinical-plan-oms721-approval-iga --Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent Thu, 17 Jan 2019 08:15:51 -0500 Omeros Corporation News Releases 11431 Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-record-high-quarterly-revenue – Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 . Mon, 14 Jan 2019 07:31:00 -0500 Omeros Corporation News Releases 11426 Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy https://investor.omeros.com/news-releases/news-release-details/omeros-establishes-independent-academic-leadership-committee-its -- Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research -- SEATTLE --(BUSINESS WIRE)--Dec. 20, 2018-- Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for Thu, 20 Dec 2018 08:30:11 -0500 Omeros Corporation News Releases 11421